News Image

Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 for the Treatment of Chronic Hepatitis B Virus Infection

Provided By GlobeNewswire

Last update: Jun 18, 2024

SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the first participant has been dosed in the Phase 1b trial of ABI-4334, a next-generation capsid assembly modulator (CAM) candidate in development for the treatment of chronic hepatitis B virus (HBV) infection.

Read more at globenewswire.com

ASSEMBLY BIOSCIENCES INC

NASDAQ:ASMB (6/2/2025, 4:04:09 PM)

15.4

+1.25 (+8.83%)



Find more stocks in the Stock Screener

Follow ChartMill for more